Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

NCT05765955 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

DRUG: POLB 001
DRUG: Placebo

Sponsor

Poolbeg Pharma plc